

Citations

1. Burkhart CG, Burkhart CN. Phenylalanine with UVA for the treatment of vitiligo needs more testing for possible side effects. *J Am Acad Dermatol* 1999;40:1015.
2. Karstaedt PJ, Pincus JH. Aspartame use in Parkinson's disease. *Neurology* 1993;43:611-613.
3. Balagot RC, Ehrenpreis S, Greenberg J, Hyodo M. d-Phenylalanine in human chronic pain. In: Ehrenpreis S, Sicuteri F, eds. *Degradation of Endogenous Opioids: Its Relevance in Human Pathology and Therapy*. New York: Raven Press; 1983.
4. Ehrenpreis S. Analgesic properties of enkephalinase inhibitors: animal and human studies. *Prog Clin Biol Res* 1985;192:363-370.
5. Balagot RC, Ehrenpreis S, Kubota K, Greenberg J. Analgesia in mice and humans by D-phenylalanine: relation to inhibition of enkephalin degradation and enkephalin levels. *Adv Pain Res Ther* 1983;5:289-293.
6. Budd K. Use of d-phenylalanine, an enkephalinase inhibitor, in the treatment of intractable pain. *Adv Pain Res Ther* 1983;5:305-308.
7. Walsh NE, Ramamurthy S, Schoenfeld LS, Hoffman J. d-Phenylalanine was not found to exhibit opiate receptor mediated analgesia in monkeys. *Pain* 1986;26:409-410.
8. Walsh NE, Ramamurthy S, Schoenfeld L, Hoffman J. Analgesic effectiveness of d-phenylalanine in chronic pain patients. *Arch Phys Med Rehabil* 1986;67:436-439.
9. Kitade T, Odahara Y, Shinohara S et al. Studies on the enhanced effect of acupuncture analgesia and acupuncture anesthesia by d-phenylalanine (2nd report): schedule of administration and clinical effects in low back pain and tooth extraction. *Acupunct Electrother Res* 1990;15:121-135.
10. Crane GE. Clinical psychopharmacology in its 20th year: late, unanticipated effects of neuroleptics may limit their use in psychiatry. *Science* 1973;181:124-128.
11. Yassa R, Nastase C, Camille Y, Belzile L. Tardive dyskinesia in a psychogeriatric population. In: Wolf MD, Mosnaim AD, eds. *Tardive Dyskinesia*. Washington, DC: American Psychiatric Press; 1988.
12. Hashim S, Sajjad, A. Vitamin E in the treatment of tardive dyskinesia: a preliminary study over 7 months at different doses. *Int Clin Psychopharmacol* 1988;147-155.
13. Adler LA, Peselow E, Rotrosen J et al. Vitamin E treatment of tardive dyskinesia. *Am J Psychiatry* 1993;150:1405-1407.
14. Lerner V, Miodownik C, Kapsan A et al. Vitamin B(6) in the treatment of tardive dyskinesia: a double-blind, placebo-controlled, crossover study. *Am J Psychiatry* 2001;158:1511-1514.
15. Harvie MN, Campbell IT, Howell A, Thatcher N. Acceptability and tolerance of a low tyrosine and phenylalanine diet in patients with advanced cancer: a pilot study. *J Hum Nutr Diet* 2002;15:193-202.
16. Moll-Navarro MJ, Merino M, Casabo VG et al. Interaction of taurine on baclofen intestinal absorption: a nonlinear mathematical treatment using differential equations to describe kinetic inhibition models. *J Pharm Sci* 1996;85:1248-1254.
17. Cercos-Fortea T, Polache A, Nacher A et al. Influence of leucine on intestinal baclofen absorption as a model compound of neutral alpha-aminoacids. *Biopharm Drug Dispos* 1995;16:563-577.
18. Nacher A, Polache A, Moll-Navarro MJ et al. Influence of gamma-aminobutyric acid on baclofen intestinal absorption. *Biopharm Drug Dispos* 1994;15:373-382.
19. Polache A, Pla-Delfina JM, Merino M. Partially competitive inhibition of intestinal baclofen absorption by beta-alanine, a nonessential dietary aminoacid. *Biopharm Drug Dispos* 1991;12:647-660.
20. Merino M, Polache A, Peris-Ribera JE et al. Absorption kinetics of beta-alanine as model compound in rat small intestine. *Biochim Biophys Acta* 1989;986:1-7.
21. Merino M, Peris-Ribera JE, Torres-Molina F et al. Evidence of a specialized transport mechanism for the intestinal absorption of baclofen. *Biopharm Drug Dispos* 1989;10:279-297.
22. Cejudo-Ferragud E, Nacher A, Polache A et al. Evidence of competitive inhibition for the intestinal absorption of baclofen by phenylalanine. *Int J Pharmaceut* 1996;132:63-69.
23. Robertson DR, Higginson I, Macklin BS et al. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. *Br J Clin Pharmacol* 1991;31:413-417.
24. Wade LA, Katzman R. Rat brain regional uptake and decarboxylation of l-dopa following carotid injection. *Am J Physiol* 1975;228:352-359.
25. Nutt JG, Woodward WR, Hammerstad JP et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. *N Engl J Med* 1984;310:483-488.
26. Woodward WR, Olanow CW, Beckner RM et al. The effect of l-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF l-dopa levels and clinical responses. *Neurology* 1993;43:1704-1708.
27. Ehrenpreis S. d-Phenylalanine and other enkephalinase inhibitors as pharmacological agents: implications for some important therapeutic application. *Subst Alcohol Actions Misuse* 1982;3:231-239.

Citations and Reference Literature: Phenylalanine

28. Dove B, Morgenstern E, Gores E. [Analgesic effect, tolerance development and dependence potential of d-phenylalanine]. *Pharmazie* 1985;40:648-650.
29. Dove B, Morgenstern E, Gores E. [The analgesic action of d-phenylalanine in combination with morphine or methadone]. *Pharmazie* 1991;46:875-877.
30. Russell AL, McCarty MF. dl-Phenylalanine markedly potentiates opiate analgesia: an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system. *Med Hypotheses* 2000;55:283-288.
31. Ehrenpreis S, Balagot RC, Myles S et al. Further studies on the analgesic activity of d-phenylalanine in mice and humans. In: Way EL, ed. *Proceedings of the International Narcotic Research Club Convention*; 1979:379-382.
32. Gardos G, Cole JO, Matthews JD et al. The acute effects of a loading dose of phenylalanine in unipolar depressed patients with and without tardive dyskinesia. *Neuropsychopharmacology* 1992;6:241-247.
33. Mosnik DM, Spring B, Rogers K, Baruah S. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. *Neuropsychopharmacology* 1997;16:136-146.
34. Schultz SK, Ellingrod V, Fleming FW, Andreasen NC. The association between risk factors for tardive dyskinesia and phenylalanine-induced abnormal movements in schizophrenia. *Hum Psychopharmacol* 2001;16:273-277.
35. Sabelli HC, Javadi JI. Phenylethylamine modulation of affect: therapeutic and diagnostic implications. *J Neuropsychiatry Clin Neurosci* 1995;7:6-14.
36. Sabelli HC, Fawcett J, Gusovsky F et al. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. *J Clin Psychiatry* 1986;47:66-70.
37. Sabelli H, Fink P, Fawcett J, Tom C. Sustained antidepressant effect of PEA replacement. *J Neuropsychiatry Clin Neurosci* 1996;8:168-171.
38. Paetsch PR, Greenshaw AJ. 2-Phenylethylamine-induced changes in catecholamine receptor density: implications for antidepressant drug action. *Neurochem Res* 1993;18:1015-1022.
39. Birkmayer W, Riederer P, Linauer W, Knoll J. l-Deprenyl plus l-phenylalanine in the treatment of depression. *J Neural Transm* 1984;59:81-87.
40. Sabelli HC. Rapid treatment of depression with selegiline-phenylalanine combination. *J Clin Psychiatry* 1991;52:137.
41. Sabelli H, Fahrer R, Medina RD, Ortiz Fragola E. Phenylethylamine relieves depression after selective MAO-B inhibition. *J Neuropsychiatry Clin Neurosci* 1994;6:203.
42. Szabo A, Billett E, Turner J. Phenylethylamine, a possible link to the antidepressant effects of exercise? *Br J Sports Med* 2001;35:342-343.
43. Bergman J, Yasar S, Winger G. Psychomotor stimulant effects of beta-phenylethylamine in monkeys treated with MAO-B inhibitors. *Psychopharmacology (Berl)* 2001;159:21-30.
44. Kravitz HM, Sabelli HC, Fawcett J. Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders. *J Am Osteopath Assoc* 1984;84:119-123.
45. Prince AP, Leklem JE. Vitamin B-6 status of school-aged patients with phenylketonuria. *Am J Clin Nutr* 1994;60:262-268.

Reference Literature

- Ambrus CM, Anthone S, Horvath C, et al. Extracorporeal enzyme reactors for depletion of phenylalanine in phenylketonuria. *Ann Intern Med* 1987;106(4):531-537.
- Anonymous. Phenylalanine fails to help chronic back pain patients. *Family Pract News* 1987;17(3):37.
- Antoniou C, Katsambas A. Guidelines for the treatment of vitiligo. *Drugs* 1992;43(4):490-498.
- Balagot RC, Ehrenpreis S, Greenberg J, et al. D-phenylalanine in human chronic pain. In: Ehrenpreis S, Sicuteri F, eds. *Degradation of endogenous opioids: its relevance in human pathology and therapy*. New York: Raven Press; 1983.
- Balagot RC, Ehrenpreis S, Kubota K, et al. Analgesia in mice and humans by D-phenylalanine: relation to inhibition of enkephalin degradation and enkephalin levels. *Adv Pain Res Ther* 1983;5:289-293.
- Beckmann H, Athen D, Olteanu M, et al. DL-phenylalanine versus imipramine: a double-blind controlled study. *Arch Psychiat Nervenkr* 1979;227:49-58.
- Blum K, Briggs AH, Trachtenberg MC, et al. Enkephalinase inhibition: regulation of ethanol intake in genetically predisposed mice. *Alcohol* 1987;4(6):449-456.
- Boulton AA. Phenylethylaminergic modulation of catecholaminergic neurotransmission. *Prog Neuropsychopharmacol Biol Psychiatry* 1991;15(2):139-156. (Review)
- Brown P, Funk SC. Tardive dyskinesia: barriers to the professional recognition of an iatrogenic disease. *J Health Soc Behav* 1986;27(2):116-132. (Review)

Citations and Reference Literature: Phenylalanine

- Bucci LR. Nutrition applied to injury rehabilitation and sports medicine. Boca Raton, FL: CRC Press; 1994:43-44.
- Budd K. Use of D-phenylalanine, an enkephalinase inhibitor, in the treatment of intractable pain. *Adv Pain Res Ther* 1983;5:305-308.
- Burgard P, Bremer HJ, Buhrdel P, et al. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. *Eur J Pediatr* 1999;158(1):46-54.
- Burkhardt CG, Burkhardt CN. Phenylalanine with UVA for the treatment of vitiligo needs more testing for possible side effects. *J Am Acad Dermatol* 1999;40(6 Pt 1):1015. (Letter)
- Caballero B, Mahon BE, Rohr FJ, et al. Plasma amino acid levels after single-dose aspartame consumption in phenylketonuria, mild hyperphenylalaninemia, and heterozygous state for phenylketonuria. *J Pediatr* 1986;109(4):668-671.
- Camacho F, Mazuecos J. Treatment of vitiligo with oral and topical phenylalanine: 6 years of experience. *Arch Dermatol* 1999;135(2):216-217.
- Cormane RH, Siddiqui AH, Westerhof W, et al. Phenylalanine and UVA light for the treatment of vitiligo. *Arch Dermatol Res* 1985;277(2):126-130.
- Doudet D, McLellan CA, Aigner TG, et al. Delayed L-phenylalanine infusion allows for simultaneous kinetic analysis and improved evaluation of specific-to-non-specific fluorine-18-DOPA uptake in brain. *J Nucl Med* 1992;33(7):1383-1389.
- Ehrenpreis S, Balagot RC, Comaty JE, et al. Naloxone reversible analgesia in mice produced by D-phenylalanine and hydrocinnamic acid, inhibitors of carboxypeptidase A. In: Bonica JJ, Liebeskind JC, Albe-Fessard DG, eds. *Advances in pain research and therapy*. Vol. 3. New York: Raven Press; 1978:479-488.
- Ehrenpreis S, Balagot RC, Myles S, et al. Further studies on the analgesic activity of D-phenylalanine in mice and humans. In: Way EL, ed. *Proceedings of the International Narcotic Research Club Convention*. 379-382;1979.
- Ehrenpreis S. Analgesic properties of enkephalinase inhibitors: animal and human studies. *Prog Clin Biol Res* 1985;192:363-370.
- Ehrenpreis S. D-phenylalanine and other enkephalinase inhibitors as pharmacological agents: implications for some important therapeutic application. *Subst Alcohol Actions Misuse* 1982;3(4):231-239.
- Ehrenpreis S. D-phenylalanine and other enkephalinase inhibitors as pharmacological agents: implications for some important therapeutic application. *Acupunct Electrother Res* 1982;7(2-3):157-172.
- Ehrenpreis S. Pharmacology of enkephalinase inhibitors: animal and human studies. *Acupunct Electrother Res* 1985;10(3):203-208.
- Fischer E, Heller B, Nachon M, et al. Therapy of depression by phenylalanine: preliminary note. *Arzneimittelforschung* 1975;25(1):132.
- Fugh-Berman A, Cott JM. Dietary supplements and natural products as psychotherapeutic agents. *Psychomatic Med* 1999;61:712-728. (Review)
- Grevet EH, Tietzmann MR, Shansis FM, et al. Behavioural effects of acute phenylalanine and tyrosine depletion in healthy male volunteers. *J Psychopharmacol* 2002;16(1):51-55.
- Haavik J. L-DOPA is a substrate for tyrosine hydroxylase. *J Neurochem* 1997;69(4):1720-1728.
- Heller B. Pharmacological and clinical effects of D-phenylalanine in depression and Parkinson's disease. In: Mosnaim AD, Wolf ME, eds. *Modern pharmacology-toxicology, noncatecolic phenylethylamines*, part 1. New York: Marcel Dekker; 1978:397-417.
- Heller B, Fischer E, Martin R. Therapeutic action of D-phenylalanine in Parkinson's disease. *Arzneimittelforschung* 1976;26(4):577-579.
- Hsieh MC, Berry HK. Distribution of phenylalanine hydroxylase (EC 1.14.3.1) in liver and kidney of vertebrates. *J Exp Zool* 1979;208(2):161-167.
- Kitade T, Odahara Y, Shinohara S, et al. Studies on the enhanced effect of acupuncture analgesia and acupuncture anesthesia by D-phenylalanine (2nd report): schedule of administration and clinical effects in low back pain and tooth extraction. *Acupunct Electrother Res* 1990;15:121-135.
- Kovacs SO. Vitiligo. *J Am Acad Dermatol* 1998;38(5 Pt 1):647-666.
- Kravitz HM, Sabelli HC, Fawcett J. Dietary supplements of phenylalanine and other amino acid precursors of brain neuroamines in the treatment of depressive disorders. *J Am Osteopathic Assoc* 1984;84(Suppl):119-123.
- Leandro P, Rivera I, Lechner MC, et al. The V388M mutation results in a kinetic variant form of phenylalanine hydroxylase. *Mol Genet Metab* 2000;69:204-212.
- Lehmann WD, Theobald N, Fischer R, et al. Stereospecificity of phenylalanine plasma kinetics and hydroxylation in man following oral application of a stable isotope-labelled pseudo-racemic mixture of L- and D-phenylalanine. *Clin Chim Acta* 1983;128(2-3):181-198.
- Leyton M, Young SN, Pihl RO, et al. A comparison of the effects of acute tryptophan depletion and acute phenylalanine/tyrosine depletion in healthy women. *Adv Exp Med Biol* 1999;467:67-71.
- Maes M, Verkerk R, Delmeire L, et al. Serotonergic markers and lowered plasma branched-chain-amino acid concentrations in fibromyalgia. *Psychiatry Res* 2000;97(1):11-20.
- Mann J, Peselow ED, Snyderman S, et al. D-phenylalanine in endogenous depression. *Am J Psychiatry* 1980;137(12):1611-1612.
- Marz R. *Medical nutrition from Marz*. 2nd ed. Portland, OR: Omni Press; 1997.

Citations and Reference Literature: Phenylalanine

- Matalon R, Michals K, Sullivan D, et al. Aspartame consumption in normal individuals and carriers for phenylketonuria (PKU): presented at Dietary Phenylalanine and Brain Function: proceedings of the First International Meeting on Dietary Phenylalanine and Brain Function, Washington, D.C., May 8-10, 1987. *Dietary Phenylalanine Brain Funct* 1988;41-52.
- Matsumoto M. [Experimental and clinical application of amino acid imbalance for the treatment of malignant diseases, with special reference to phenylalanine imbalance (author's transl).] *Igaku Kenkyu* 1977;47(4):195-294. [Japanese]
- Meyers S. Use of neurotransmitter precursors for treatment of depression. *Altern Med Rev* 2000;5(1):64-71.
- Montastruc JL, Chaumerliac C, Desboeuf K, et al. Adverse drug reactions to selegiline: a review of the French pharmacovigilance database. *Clin Neuropharmacol* 2000;23(5):271-275. (Review)
- Mosnik DM, Spring B, Rogers K, et al. Tardive dyskinesia exacerbated after ingestion of phenylalanine by schizophrenic patients. *Neuropsychopharmacology* 1997;16(2):136-146.
- Nutt JG, Fellman JH. Pharmacokinetics of levodopa. *Clin Neuropharmacol* 1984;7(1):35-49. (Review)
- Nutt JG, Woodward WR. Levodopa pharmacokinetics and pharmacodynamics in fluctuating parkinsonian patients. *Neurology* 1986;36(6):739-744.
- Nutt JG, Woodward WR, Hammerstad JP, et al. The "on-off" phenomenon in Parkinson's disease: relation to levodopa absorption and transport. *N Engl J Med* 1984;310(8):483-488.
- Partridge WM. Potential effects of the dipeptide sweetener aspartame on the brain. In: Wurtman RJ, Wurtman JJ, eds. *Nutrition and the brain*. Vol 7. New York: Raven Press; 1986:199-241.
- Partridge WM. The safety of aspartame. *JAMA* 1986;256(19):2678. (Letter)
- Pietz J. Neurological aspects of adult phenylketonuria. *Curr Opin Neurol* 1998;11:679-688.
- Pietz J, Dunkelmann R, Rupp A, et al. Neurological outcome in adult patients with early-treated phenylketonuria. *Eur J Pediatr* 1998;157:824-830.
- Rascol O, Fabre N. Dyskinesia: L-dopa-induced and tardive dyskinesia. *Clin Neuropharmacol* 2001;24(6):313-323. (Review)
- Rezvani I. Defects in metabolism of amino acids; phenylalanine. In: Behrman RE, Kliegman RM, Jenson HB, eds. *Nelson textbook of pediatrics*. 16th ed. Philadelphia: Saunders; 2000:344-346.
- Richardson MA. *Amino acids in psychiatric disease*. Washington, DC: Psychiatric Press; 1990.
- Russell AL, McCarty MF. DL-phenylalanine markedly potentiates opiate analgesia: an example of nutrient/pharmaceutical up-regulation of the endogenous analgesia system. *Med Hypotheses* 2000;55(4):283-288. (Review)
- Sabelli HC, Fawcett J, Gusovsky F, et al. Clinical studies on the phenylethylamine hypothesis of affective disorder: urine and blood phenylacetic acid and phenylalanine dietary supplements. *J Clin Psychiatry* 1986;47(2):66-70.
- Sabelli HC, Javaid JJ. Phenylethylamine modulation of affect: therapeutic and diagnostic implications. *J Neuropsychiatry Clin Neurosci* 1995;7(1):6-14. (Review)
- Schallreuter KU, Zschesche M, Moore J, et al. In vivo evidence for compromised phenylalanine metabolism in vitiligo. *Biochem Biophys Res Commun* 1998;243(2):395-399.
- Schulpis CH, Antoniou C, Michas T, et al. Phenylalanine plus ultraviolet light: preliminary report of a promising treatment for childhood vitiligo. *Pediatr Dermatol* 1989;6(4):332-335.
- Shils ME, Olson JA, Shike M, et al. *Modern nutrition in health and disease*. 9th ed. Baltimore: Williams & Wilkins; 1999(41):1010.
- Siddiqui AH, Stolk LM, Bhaggoe R, et al. L-phenylalanine and UVA irradiation in the treatment of vitiligo. *Dermatology* 1994;188(3):215-218.
- Stone TW. A comparison of the effects of morphine, enkephalin, kyotorphin and D-phenylalanine on rat central neurones. *Br J Pharmacol* 1983;79(1):305-312.
- Sze PY. Pharmacological effects of phenylalanine on seizure susceptibility: an overview. *Neurochem Res* 1989;14:2:103-111.
- Thorpe JM, Roberts SA, Ball RO, et al. Prior protein intake may affect phenylalanine kinetics measured in healthy adult volunteers consuming 1 g protein: kg-1: d-1. *J Nutr* 1999;129(2):343-348.
- Walsh NE, Ramamurthy S, Schoenfeld L, et al. Analgesic effectiveness of D-phenylalanine in chronic pain patients. *Arch Phys Med Rehabil* 1986;67(7):436-439.
- Werbach MR. *Nutritional influences on illness*. 2nd ed. Tarzana, CA: Third Line Press; 1993:159-160,384,434,494-495,506,580,613-614,636. (Review)
- Werbach MR. *Nutritional influences on mental illness: a sourcebook of clinical research*. Tarzana, CA: Third Line Press; 1991:141-142. (Review)
- Winter A. New treatment for multiple sclerosis. *Neurol Orthop J Med Surg* 1984;5:39-43.
- Woodward WR, Olanow CW, Beckner RM, et al. The effect of L-dopa infusions with and without phenylalanine challenges in parkinsonian patients: plasma and ventricular CSF L-dopa levels and clinical responses. *Neurology* 1993;43(9):1704-1708.

Citations and Reference Literature: Phenylalanine

- Zametkin AJ, Karoum F, Rapoport JL. Treatment of hyperactive children with D-phenylalanine. *Am J Psychiatry* 1987;144(6):792-794.
- Zhao G, Gu T, Li Z. Inherited disturbances of phenylalanine metabolic kinetics in essential hypertension. *Chin Med J (Engl)* 2001;114(8):799-802.
- Zhang ZR, McDonough SI, McCarty NA. Interaction between permeation and gating in a putative pore domain mutant in the cystic fibrosis transmembrane conductance regulator. *Biophys J* 2000;79(1):298-313.